Stallergenes Greer, a global biopharmaceutical company specializing in allergy immunotherapy (AIT), has announced the transition of Actair® promotional activities in Japan to CEOLIA Pharma, Inc., a newly established joint venture between Stallergenes Greer and Shionogi & Co., Ltd. This strategic move is aimed at expanding access to allergy treatments while accelerating commercial growth in the Japanese market.
🌿 About Actair®
Actair® is a sublingual immunotherapy (SLIT) tablet designed for the treatment of house dust mite-induced allergic rhinitis, a common condition in Japan. It is the first SLIT tablet approved in Japan for this indication and offers patients a non-invasive, at-home treatment alternative.
🤝 Why the Transition Matters
By transferring promotional responsibilities to CEOLIA Pharma, the companies are:
-
📈 Strengthening commercial execution through a locally-focused entity
-
🌏 Combining global expertise with regional insight, leveraging Shionogi’s deep knowledge of the Japanese pharmaceutical landscape
-
🧬 Enhancing patient access to a clinically proven, long-term treatment option for allergy sufferers
CEOLIA Pharma is well-positioned to scale outreach to healthcare providers, improve patient education, and drive broader adoption of immunotherapy solutions in Japan.
🚀 A Step Toward Growth in APAC
This transition reflects Stallergenes Greer’s long-term commitment to growth in the Asia-Pacific region and aligns with its strategy to expand access to AIT solutions worldwide. CEOLIA Pharma will act as a central hub for both promotion and future product introductions, paving the way for innovation in allergy care.
👉 Read the full analysis at Actair® Promotion in Japan Transitions to CEOLIA Pharma
👉 Read more IT Business Today
Comments
0 comment